{"schema_version":"secwatch.filing_event.v1","accession":"0001628280-24-046856","form_type":"8-K","ticker":"ABSI","cik":"0001672688","company_name":"Absci Corp","filed_at":"2024-11-12T23:59:59+00:00","discovered_at":"2026-05-14T18:03:09.180928+00:00","generated_at":"2026-05-30T02:00:02.328041+00:00","sec_items":["2.02","8.01","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Absci Q3 revenue $1.7M, net loss $27.4M; achieves AstraZeneca milestone, lowers 2024 cash burn guidance to ~$75M","bullets":["Revenue $1.7M (up from $0.7M YoY); net loss $27.4M vs $22.0M; cash $127.1M at Sept 30, 2024.","First milestone achieved under AstraZeneca AI antibody collaboration; entered Twist Bioscience partnership for novel antibody design.","Gross cash use expected ~$75M for FY2024, below prior guidance of ~$80M; cash runway into first half 2027.","ABS-101 on track for Phase 1 initiation H1 2025 with interim data H2 2025; ABS-201 candidate selection expected H2 2024.","R&D expenses $18.0M (up from $11.0M) driven by IND-enabling studies for ABS-101; SG&A $9.3M (down from $9.5M)."],"urls":{"canonical":"https://secwatch.observer/filing/0001628280-24-046856","json":"https://secwatch.observer/filing/0001628280-24-046856.json","markdown":"https://secwatch.observer/filing/0001628280-24-046856.md","text":"https://secwatch.observer/filing/0001628280-24-046856.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1672688/000162828024046856/0001628280-24-046856-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1672688/000162828024046856/absc-20241112.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-30T02:00:02.328041+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}